<DOC>
	<DOC>NCT00069251</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy and safety of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence</brief_summary>
	<brief_title>Bupropion for the Treatment of Methamphetamine Dependence - 1</brief_title>
	<detailed_description>A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks following treatment. Adaptive randomization will be used to balance treatment groups based on gender.</detailed_description>
	<mesh_term>Amphetamine-Related Disorders</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Subject must have methamphetamine dependence as determined by the DSMIV diagnosis Subject must be willing to comply with study procedures. Ability to verbalize understanding of consent form, provide written consent, and verbalize willingness to complete study procedures Be able to comply with protocol requirements Please contact site for more information.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>amphetamine dependence</keyword>
</DOC>